Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Operating Leases (2019 - 2025)

Sangamo Therapeutics (SGMO) has 8 years of Operating Leases data on record, last reported at $25.4 million in Q3 2025.

  • For Q3 2025, Operating Leases fell 8.31% year-over-year to $25.4 million; the TTM value through Sep 2025 reached $25.4 million, down 8.31%, while the annual FY2024 figure was $26.3 million, 21.67% down from the prior year.
  • Operating Leases reached $25.4 million in Q3 2025 per SGMO's latest filing, up from $23.5 million in the prior quarter.
  • Across five years, Operating Leases topped out at $44.1 million in Q4 2021 and bottomed at $23.5 million in Q2 2025.
  • Average Operating Leases over 5 years is $34.4 million, with a median of $36.1 million recorded in 2021.
  • Peak YoY movement for Operating Leases: rose 14.74% in 2021, then fell 21.67% in 2024.
  • A 5-year view of Operating Leases shows it stood at $44.1 million in 2021, then fell by 11.51% to $39.0 million in 2022, then decreased by 14.03% to $33.5 million in 2023, then dropped by 21.67% to $26.3 million in 2024, then fell by 3.16% to $25.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $25.4 million in Q3 2025, $23.5 million in Q2 2025, and $24.9 million in Q1 2025.